Haleon PLC Sponsored ADR (NYSE:HLN) Sees Significant Decline in Short Interest

Haleon PLC Sponsored ADR (NYSE:HLN) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totaling 12,355,479 shares, a decrease of 35.9% from the March 31st total of 19,282,381 shares. Based on an average daily volume of 6,562,399 shares, the short-interest ratio is presently 1.9 days. Currently, 0.3% of the shares of the stock are sold short.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently modified their holdings of the stock. SOA Wealth Advisors LLC. increased its holdings in shares of Haleon by 60.5% in the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department boosted its position in shares of Haleon by 167.4% during the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after purchasing an additional 2,051 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Haleon by 101.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after acquiring an additional 1,433 shares in the last quarter. Atlantic Union Bankshares Corp lifted its position in Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after acquiring an additional 2,758 shares in the last quarter. Finally, Stance Capital LLC bought a new stake in Haleon in the 3rd quarter valued at $34,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HLN. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Argus raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Price Performance

Shares of NYSE HLN traded down $0.05 during mid-day trading on Thursday, hitting $9.26. 8,797,556 shares of the stock were exchanged, compared to its average volume of 6,247,939. The company has a market cap of $41.22 billion, a P/E ratio of 23.73, a PEG ratio of 1.97 and a beta of 0.26. The stock’s fifty day simple moving average is $10.05 and its two-hundred day simple moving average is $9.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon has a twelve month low of $8.71 and a twelve month high of $11.42.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion for the quarter. As a group, analysts forecast that Haleon will post 0.56 EPS for the current fiscal year.

Haleon Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a dividend yield of 266.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s dividend payout ratio is 64.10%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.